Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To assess the total metabolic effect ratios of a new insulin glargine formulation versus
Lantus®
Secondary Objectives:
- To assess the exposure ratios of a new insulin glargine formulation versus Lantus®
- To compare the duration of action of a new insulin glargine formulation versus Lantus®
- To explore the dose response and dose exposure relationship of a new insulin glargine
formulation
- To assess the safety and tolerability of a new insulin glargine formulation